Uae Point-Of-Care Molecular Diagnostics Market Size & Outlook
- Clinical Diagnostics
- Cancer Diagnostics
- Point-of-Care Molecular Diagnostics Market Outlook
- Cancer Diagnostics
Global Market
Related Markets
Ask Prism AI anything about the point-of-care molecular diagnostics market
Get a cited answer from GVR research in seconds: segment shares, growth drivers, regulation and forecast assumptions.
UAE point-of-care molecular diagnostics market highlights
- The UAE point-of-care molecular diagnostics market generated a revenue of USD 45.2 million in 2024 and is expected to reach USD 79.6 million by 2033.
- The UAE market is expected to grow at a CAGR of 6.7% from 2025 to 2033.
- In terms of segment, infectious diseases was the largest revenue generating application in 2024.
- Oncology is the most lucrative application segment registering the fastest growth during the forecast period.
Point-of-care molecular diagnostics market data book summary
| Market revenue in 2024 | USD 45.2 million |
| Market revenue in 2033 | USD 79.6 million |
| Growth rate | 6.7% (CAGR from 2025 to 2033) |
| Largest segment | Infectious diseases |
| Fastest growing segment | Oncology |
| Historical data | 2021 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Oncology, Prenatal Testing, Endocrinology, Other Applications, Hematology, Infectious Diseases |
| Key market players worldwide | Roche, Abbott Laboratories, Qiagen NV, Bayer AG, Nova Biomedical, Danaher Corp, Nipro Corp, Bio-Rad Laboratories Inc, Agilent Technologies Inc, BioMerieux SA, OraSure Technologies Inc, Abaxis |
Other key industry trends
- In terms of revenue, UAE accounted for 0.6% of the global point-of-care molecular diagnostics market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Middle East & Africa, Saudi Arabia point-of-care molecular diagnostics market is projected to lead the regional market in terms of revenue in 2033.
- Saudi Arabia is the fastest growing regional market in Middle East & Africa and is projected to reach USD 98.8 million by 2033.
Being a high-income country, the UAE government aims to provide universal access to updated and advanced healthcare services by 2021. Due to its vast financial resources and adequate government funding, the point-of-care molecular diagnostics market in UAE is likely to progress steadily. The increasing prevalence of chronic diseases is one of the major factors fueling the growth in the UAE market.
According to World Life Expectancy, CVD, stroke, diabetes, and COPD were some of the major causes of death in the country in 2020. It is also observed that nearly 23.4% to 24.7% of men smoke cigarettes in this country, which further increases the risk of lung & cardiovascular diseases, boosting the demand for testing. In addition, the presence of laboratories conducting point-of-care molecular diagnostics tests for infectious diseases is expected to boost market growth.
For instance, National Reference Laboratory conducts molecular diagnosis using RT-PCR for human papillomavirus, hepatitis, Sexually Transmitted Infections (STIs), HIV, and other infectious diseases.
No credit card required*
Publish Date: Aug 05, 2025
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
- Turnaround
- 5–10 working days
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Point-Of-Care Molecular Diagnostics Market Scope
Point-Of-Care Molecular Diagnostics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Abbott Laboratories | View profile | 114,000 | 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400 | www.abbottinvestor.com |
| BioMerieux SA | View profile | 13,982 | Marcy l’Etoile, Lyon, France, 69280 | www.biomerieux.com |
| Danaher Corp | View profile | 63,000 | 2200 Pennsylvania Avenue, N.W., Suite 800W, Washington, DC, United States, 20037-1701 | www.danaher.com |
| Agilent Technologies Inc | View profile | 17,700 | 5301 Stevens Creek Boulevard, Santa Clara, CA, United States, 95051 | www.agilent.com |
| Bio-Rad Laboratories Inc | View profile | 8,030 | 1000 Alfred Nobel Drive, Hercules, CA, United States, 94547 | www.bio-rad.com |
| Qiagen NV | View profile | 5,900 | Hulsterweg 82, Venlo, LI, Netherlands, 5912 PL | www.qiagen.com |
| Nova Biomedical | View profile | 501-1000 | Waltham, Massachusetts, United States, North America | www.novabio.us |
| Bayer AG | View profile | 99,723 | Kaiser-Wilhelm-Allee 1, Leverkusen, NW, Germany, 51368 | www.bayer.com |
| Nipro Corp | View profile | 39,713 | 3-9-3 Honjo-Nishi Kita-ku, Osaka, Japan, 531-8510 | www.nipro.co.jp |
| Roche | View profile | 10001+ | Basel, Basel-Stadt, Switzerland, Europe | www.roche.com |
UAE Point-of-Care Molecular Diagnostics Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Point-of-Care Molecular Diagnostics Market Outlook will help companies and investors design strategic landscapes.
Infectious Diseases was the largest segment with a revenue share of 49.34% in 2024.
Horizon Databook has segmented the Uae point-of-care molecular diagnostics market based on oncology, prenatal testing, endocrinology, other applications, hematology, infectious diseases covering the revenue growth of each sub-segment from 2021 to 2033.
Being a high-income country, the UAE government aims to provide universal access to updated and advanced healthcare services by 2021. Due to its vast financial resources and adequate government funding, the point-of-care molecular diagnostics market in UAE is likely to progress steadily. The increasing prevalence of chronic diseases is one of the major factors fueling the growth in the UAE market.
According to World Life Expectancy, CVD, stroke, diabetes, and COPD were some of the major causes of death in the country in 2020. It is also observed that nearly 23.4% to 24.7% of men smoke cigarettes in this country, which further increases the risk of lung & cardiovascular diseases, boosting the demand for testing. In addition, the presence of laboratories conducting point-of-care molecular diagnostics tests for infectious diseases is expected to boost market growth.
For instance, National Reference Laboratory conducts molecular diagnosis using RT-PCR for human papillomavirus, hepatitis, Sexually Transmitted Infections (STIs), HIV, and other infectious diseases.
- Uae Point-Of-Care Molecular Diagnostics Market Application Outlook (Revenue, USD Million , 2021-2033)
- Oncology
- Prenatal Testing
- Endocrinology
- Other Applications
- Hematology
- Infectious Diseases
- Uae Point-Of-Care Molecular Diagnostics Market Technology Outlook (Revenue, USD Million , 2021-2033)
- PCR-based
- Genetic Sequencing based
- Hybridization based
- Microarray based
- Uae Point-Of-Care Molecular Diagnostics Market Test Location Outlook (Revenue, USD Million , 2021-2033)
- OTC
- POC
- Uae Point-Of-Care Molecular Diagnostics Market End-use Outlook (Revenue, USD Million , 2021-2033)
- Decentralised Labs
- Hospitals
- Home care
- Assisted Living Healthcare Facilities
- Others
Reasons to subscribe to Point-of-Care Molecular Diagnostics Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Point-of-Care Molecular Diagnostics Market Outlook databook
- Our clientele includes a mix of Point-of-Care Molecular Diagnostics Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the UAE Point-of-Care Molecular Diagnostics Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into UAE Point-of-Care Molecular Diagnostics Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Uae Point-Of-Care Molecular Diagnostics Market, 2021-2033 (US$M)
UAE Application - Point-of-care Molecular Diagnostics Market Statistics, 2024 - 2033 (US$M)
